Yes. I'm Roman Szumski from the National Research Council, previously an executive with a health and life sciences company called MDS Inc., which included a $1 billion venture capital under management under MDS Capital Corp.
I want to agree with one of the comments Harry made with the VC that is starting to come back. People in the industry believe we're going to start to see a return of venture capital in the country. However, they're likely to take their first steps in the medical device space rather than the biotechnology space, given the shorter timeframe to return.
The other aspect that is required, aside from the mechanisms that my colleagues at the table here have described so far, is that the technology development in Canada needs to be in a more mature state before it becomes of interest to the venture capitalists. Very often, what we see is simply too early and it requires too much time. I can tell you from the perspective of the experience I've had previously, being associated with a venture capital firm, you find that the state of affairs, for example, in the U.S. is that there is a significant larger amount of money invested in a technology before they first approach the VC. In Canada we tend to be a bit immature. That's another aspect and another angle we need to think about.